Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction

Paris (ots/PRNewswire) -

Sanofi announced today, at the 71st Scientific American Diabetes
Association Sessions 2011, the results of three studies showing that
people with diabetes using Sanofi insulins Lantus(R) and/or Apidra(R)
with the insulin delivery device SoloSTAR(R) experienced greater
treatment satisfaction, better quality of life and lower fear of
hypoglycemia vs those using a premixed insulin product.

The goal of the first study[1], involving 586 patients with
uncontrolled type 2 diabetes on oral agents, was to evaluate any
changes in physical and psychological well-being, diabetes-related
symptoms, and patient satisfaction with diabetes-related care and
treatment over the study period and from baseline to endpoint.

It showed that, compared with those on twice-daily premixed 70/30
insulin aspart (premix), patients on the combination of Lantus(R)-
and Apidra(R)-based regimens experienced better quality of life as
measured by the Diabetes Quality of Life (DQoL) questionnaire, which
evaluates personal perception of improvements as a result of
treatment:

- DQoL improved significantly for all groups at all wks;
          average improvement was greater for basal Lantus(R) (insulin glargine) +
          1 prandial Apidra(R) (insulin glulisine) dose (GLARG+1) and stepwise
          addition of prandial glulisine (GLARG+0-3) vs premix (P=0.0002)
        - Compared to the glargine group, patients on premix also showed
          significantly greater hypoglycemic fear from week 12 to study end
          (P<0.05).

The goal of the second study[2], conducted with 220 type 1 and
type 2 patients from 32 sites in Canada, was to evaluate the change
in diabetes treatment satisfaction in people treated with insulin
glargine. It showed that 96% of patients experienced significant
treatment satisfaction upon switching to Lantus(R) SoloSTAR(R) from
their previous treatment: Diabetes Treatment Satisfaction
Questionnaire at 6 months = 12.0 (SD = 5.4), compared to overall
satisfaction at baseline.

The objective of the third study, LANSOLEAP[3], involving 143
adults with either type 1 or type 2 diabetes in Mexico, was to
evaluate satisfaction with the SoloSTAR(R) insulin pen by adult
patients. It showed that:

- 83% rated SoloSTAR(R) as excellent
        - 78% found SoloSTAR(R) easier to use overall, compared with their
          previous device
        - 87% preferred SoloSTAR(R) to their previous device
        - Of those who had never used a pen device, 83% felt confident
          about using SoloSTAR(R) on the same day they received the pen.

Patient satisfaction is key to improving compliance, and therefore
treatment outcomes. As a patient-centric company focused on the needs
of people with diabetes Sanofi is committed to improving treatment
satisfaction and quality of life.

Notes to editors

About the studies

Polonsky et al (referred as the first study) was a 60-week
randomized, open-label study compared adding BID premixed 70/30
insulin aspart (PREMIX), basal insulin glargine + 1 prandial insulin
glulisine dose (GLARG+1), or stepwise addition of prandial glulisine
(GLARG+0-3) in 586 patients with uncontrolled type 2 diabetes on oral
agents. The objective was to evaluate any within- and between-group
changes in 1) physical and psychological well-being, 2)
diabetes-related symptoms, and 3) patient satisfaction with
diabetes-related care and treatment over the study period and from
baseline to endpoint. While achieving similar glycemic control and
body weight changes, GLARG+1 and GLARG+0-3 were more effective than
PREMIX in FBG reduction and reaching A1C <7%, while causing less
overall hypoglycemia. Patient reported outcomes were measured at
baseline, 6, 12, 24, 36, 48, and 60 weeks to assess overall quality
of life, diabetes-specific quality of life (DQoL), hypoglycemic fear
and adjustment to illness.

Garon et al (referred as the second study) evaluated the change in
diabetes treatment satisfaction in 220 patients with type 1 or type 2
diabetes treated with Lantus(R) SoloSTAR(R). This 6-month Canadian,
observational, multicenter, prospective registry collected data in
220 T1&T2 Diabetes patients from 32 sites treated with any
combination of unmixed basal insulin, oral anti-hyperglycemic drugs
or short-acting insulins who had HbA1c > 7% or HbA1c = 7% with severe
or frequent symptomatic hypoglycemia were enrolled in the study.
Treatment satisfaction was measured by using the standard Diabetes
Treatment Satisfaction Questionnaire at baseline (DTSQs) and after 6
months (DTSQc). Patients acceptance of SoloSTAR(R) pen was assessed
using 8-item pen use questionnaire having scores from 1=excellent to
5=very poor. 56 T1DM and 164 T2DM pts were on average 39.7 (SD=12.4)
and 59.3 (SD=11.0) years old and had BMIs of 26.9 (SD=4.7) and 33.4
(SD=8.0) kg/m2, respectively.

LANSOLEAP (referred as the third study) was a multicenter,
prospective, one-arm, six to eight week observational study,
involving adults with either type 1 or type 2 diabetes (who were
either insulin users, or insulin naive and taking oral medications
and candidates for insulin therapy). The primary objective was to
evaluate satisfaction with SoloSTAR(R), evaluated by a
self-assessment questionnaire pertaining to overall acceptance
(rating of SoloSTAR(R)) and ease and continuation of use. In a second
questionnaire, insulin users assessed their preference for
SoloSTAR(R) compared with their previous device.

A total of 206 patients were enrolled, with 56 excluded for
failing to meet the minimum time of 30 days between visits. The mean
age of the 150 patients whose data could be analyzed was 53.3 years
(range 18-90 yrs); 58.7% were female, 86.6% had type 2 diabetes, 68%
had a BMI >25, and 70% had used insulin previously. The 7 patients
who did not inject insulin themselves were excluded from the
satisfaction evaluation.

About Lantus[(R)]

Lantus(R) (insulin glargine) is the first 24-hour once-daily basal
insulin analog. Lantus(R) is as effective as NPH insulin with similar
reductions in HbA1c, but is associated with lower fasting blood
glucose concentrations. People with Type 2 diabetes experience a
consistent and significant reduction in the incidence of nocturnal
hypoglycemia with Lantus(R).[4]

About Apidra[(R)]

Apidra(R) is a fast-acting insulin analog of human insulin with a
zinc-free molecular structure that maintains a rapid onset and a
short duration of action, indicated for the treatment of adults with
type 1 and type 2 diabetes. Apidra(R) offers mealtime dosing
flexibility - it can be taken 15 minutes before or within 20 minutes
after starting a meal, and in a variety of body types, from lean to
obese.

About SoloSTAR(R)

SoloSTAR(R) is Sanofi's prefilled, multi-purpose, disposable
insulin pen for the administration of Lantus(R), Apidra(R) and
Insuman(R). SoloSTAR[(R)]is the winner of a GOOD DESIGN? Award.

About the Sanofi Diabetes Division

Sanofi strives to help people manage the complex challenges of
diabetes by delivering innovative, integrated and personalized
solutions. Driven by valuable insight that comes from listening to
and engaging with people living with diabetes, the Company is forming
partnerships to offer diagnostics, therapies, services, and devices.
Sanofi markets both injectable and oral medications for people with
type 1 or type 2 diabetes. Investigational compounds in the pipeline
include an injectable GLP-1 agonist being studied as a single agent,
in combination with basal insulins, and/or in combination with oral
antidiabetic agents.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers,
develops and distributes therapeutic solutions focused on patients'
needs. Sanofi has core strengths in the field of healthcare with
seven growth platforms: diabetes solutions, human vaccines,
innovative drugs, rare diseases, consumer healthcare, emerging
markets and animal health. Sanofi is listed in Paris and in New York
.

References

1. Polonksy et al. Patient Reported Outcomes Using Twice-Daily
Insulin Aspart Premixed vs Insulin Glargine Plus 1 Prandial Insulin
Glulisine or Stepwise Addition of Glulisine to Glargine in Type 2
Diabetes Uncontrolled With Oral Agents (2316-PO) ADA 2011

2. Garon et al. SignificantImprovement in Treatment Satisfaction
for Patients (pts) With Type 1 and Type 2 Diabetes Mellitus (T1&T2DM)
After 6 Months Following the Initiation of Insulin Glargine (Lantus
SoloSTAR(R))( 2223-PO) ADA 2011

3. Arellano SM, Campuzano RR, Santoyo JC, Mauricio GL. Patient
Satisfaction with the SoloSTAR(R) Insulin Pen Device in Medical
Practice in Mexico: The LANSOLEAP Study (2218-PO) ADA 2011

4. Wang F
[http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wang%20F%22%5BAuthor%5D ]
et al. Insulin glargine: a systematic review of a long-acting insulin
analogue. Clin Ther 2003 25:1541-77

Forward Looking Statements

This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results,
events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements
are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions.
Although Sanofi's management believes that the expectations reflected
in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject
to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could cause
actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labeling and other
matters that could affect the availability or commercial potential of
such products candidates, the absence of guarantee that the products
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the
Group's ability to benefit from external growth opportunities as well
as those discussed or identified in the public filings with the SEC
and the AMF made by Sanofi, including those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking
Statements" in Sanofi's annual report on Form 20-F for the year ended
December 31, 2010. Other than as required by applicable law, Sanofi
does not undertake any obligation to update or revise any
forward-looking information or statements.

Rückfragehinweis:
Contacts: Global Diabetes Division Communications, Yanyan Chang,Tel:
+49-173-689-6295, E-Mail: [email protected]

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN

print